Polatuzumab vedotin (Polivy)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism from the NCI Drug Dictionary: An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon administration, polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis.
Route: IV
Extravasation: neutral

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 1/16/2020: Initial conditional approval

Also known as

  • Code name: DCDS4501A
  • Generic name: polatuzumab vedotin-piiq
  • Brand name: Polivy

References